Cialis Compound Relicensed In US To Treat PAH Sufferers

This drug could enable many PAH sufferers to live relatively normal lives

The United Therapeutics Corporation which has licensed the active ingredient of the erectile dysfunction medication Cialis for use in another commercial drug has been given the green light from the Food & Drug Administration in America to sell and market the new product.

The United Therapeutics Corporation will now be able to manufacture commercially their new product Adcirca which has been specially formulated to treat men and women who suffer from pulmonary arterial hypertension (PAH). The drug which will be available in the recommended dose of 40mg will work by opening the arteries in the hearts and lungs of people who suffer from this rare condition. The mechanism by which the drug works is the same as the mechanism by which it opens the penile arteries and allows men to regain erectile function.

Eli Lilly who hold the rights to the active ingredient of Cialis namely Tadalafil have been working with the United Therapeutics Corporation for a number of years to generate more income from the drug. In the clinical testing which was required before the FDA would give approval men and women who suffered from pulmonary arterial hypertension, and who used the Adcirca were able to get around far more without getting out of breath and suffering from lack of oxygen.  This drug could enable many PAH sufferers to live relatively normal lives while suffering from the disease.

The erectile dysfunction drug Viagra’s active ingredient (Sildenafil) has been repackaged in another medication called Revatio and is already being used by PAH sufferers. In fact doctors have been experimenting with the class of drugs called PDE-5 Inhibitors, namely Viagra, Cialis and Levitra in treating people with all kinds of arterial problems for some years now.

The medication has not been approved for use in the European Union by the EMEA yet though it is likely that the approval will soon be forthcoming.